Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ubidecarenone - BPG Bio

Next Previous
Drug Profile

Ubidecarenone - BPG Bio

Alternative Names: API-31510; BP 31510; BPM 31510 IV; BPM 31510 Oral; BPM 31510 T; BPM 31510 Topical; BPM-31510; C-31510; c31510; Coenzyme Q10 - Cytotech; Coenzyme Q10 injectable nanosuspension; CoQ10 - Cytotech; Ubiquinone injectable nanosuspension

Latest Information Update: 28 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cytotech Labs
  • Developer BPG Bio; National Cancer Institute (USA); Stanford Cancer Institute; Stanford University; University of Miami
  • Class Antihyperlipidaemics; Antineoplastics; Benzoquinones; Cardiotonics; Cardiovascular therapies; Coenzymes; Skin disorder therapies; Small molecules
  • Mechanism of Action Antioxidants; Apoptosis stimulants; Electron transport chain complex protein modulators; Proto-oncogene protein c-bcl-2 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Epidermolysis bullosa; Pancreatic cancer; Ataxia; Glioblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Ataxia; Glioblastoma; Pancreatic cancer; Squamous cell cancer
  • Phase I/II Glioma
  • Phase I Sarcopenia
  • No development reported Epidermolysis bullosa
  • Discontinued Basal cell cancer; Leukaemia; Lung cancer; Solid tumours; Wounds

Most Recent Events

  • 20 Jan 2026 Ubidecarenone - BPG Bio receives Orphan Drug status for Ataxia in USA
  • 28 Nov 2025 No recent reports of development identified for phase-I development in Epidermolysis-bullosa(In adolescents, In adults) in USA (Topical, Cream)
  • 24 Sep 2025 BPGbio plans a phase III trial in Ataxia

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top